This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
According to the research, the pharmaceutical quality management systems market is projected to reach $3.97 billion by 2030. Some pharmaceuticalcompanies are increasing their R&D spending to increase product numbers. Also noted in the report was the shift towards cloud-based systems.
These developments are influencing pharmaceutical operations by improving research and development (R&D), manufacturing processes, and regulatory compliance. GenAI is being applied to multiple functions in pharmaceuticalcompanies. The research, which analysed more than 450 roles, highlights specific areas of transformation.
Earlier this month, the World Health Organisation (WHO) released a new guidance document with a strategic plan to counter TB on a national level. This guidance is in line with the WHO’s End TB Strategy, which aims for an 80% fall in worldwide TB incidence and a 90% decrease in TB deaths by 2030, compared with 2015.
AstraZeneca has announced its supply chain will be carbon negative by 2030. Of the world’s 20 largest pharmaceuticalcompanies, 17 have launched programmes tailored towards increasing medication access in low- and middle-income countries – up from just eight in 2010. A similar theme is evident in company filings.
According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.
According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.
According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content